BIOMAT Database Logo BIOMAT Database Logo

Effectiveness of oral and intravenous iron therapy in haemodialysis patients. 2008

C-C Jenq, and Y-C Tian, and H-H Wu, and P-Y Hsu, and J-Y Huang, and Y-C Chen, and J-T Fang, and C-W Yang
Department of Nephrology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.

Anaemia is a common and serious complication in patients with end-stage renal disease. Iron therapy is crucial in managing anaemia and maintenance of haemodialysis (HD) patients. This study investigated the efficacy of both oral and intravenous (i.v.) therapies, and the possible factors deleteriously affecting patient response to iron therapy. Forty patients on maintenance HD from a single institution were enrolled in this 6-month retrospective study. Group I (n = 20) received i.v. two ampoules of atofen (ferric chloride hexahydrate 193.6 mg) per week for a total of 6 weeks (total dosage, 960 mg). Group II (n = 20) received oral ferrous sulphate S.C. Tab (ferrous sulphate 324 mg) one pill three times daily (total dosage, 63,000 mg). Patients whose haematocrit (Hct) level increased at minimum 3% within the period were classified as responders. Iron i.v. ferric chloride (960 mg) was more effective than oral ferrous sulphate (63,000 mg) in correcting anaemia in HD patients with iron deficiency. In group I, serum triglyceride (TG) levels were significantly lower in patients responding to i.v. iron therapy than in patients with no response. In group II, serum high-sensitive C-reactive protein (hs-CRP) level was significantly lower in patients responding to oral iron therapy than patients with no response. The i.v. ferric chloride is more effective than oral ferrous sulphate in treating anaemia in HD patients with iron deficiency. Serum hs-CRP and TG levels may be parameters for predicting hyporesponsiveness to oral and i.v. iron therapies, respectively.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D002712 Chlorides Inorganic compounds derived from hydrochloric acid that contain the Cl- ion. Chloride,Chloride Ion Level,Ion Level, Chloride,Level, Chloride Ion
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females
D005290 Ferric Compounds Inorganic or organic compounds containing trivalent iron. Compounds, Ferric
D005293 Ferritins Iron-containing proteins that are widely distributed in animals, plants, and microorganisms. Their major function is to store IRON in a nontoxic bioavailable form. Each ferritin molecule consists of ferric iron in a hollow protein shell (APOFERRITINS) made of 24 subunits of various sequences depending on the species and tissue types. Basic Isoferritin,Ferritin,Isoferritin,Isoferritin, Basic

Related Publications

C-C Jenq, and Y-C Tian, and H-H Wu, and P-Y Hsu, and J-Y Huang, and Y-C Chen, and J-T Fang, and C-W Yang
Oral or parenteral iron therapy in haemodialysis patients?
January 1977, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association,
C-C Jenq, and Y-C Tian, and H-H Wu, and P-Y Hsu, and J-Y Huang, and Y-C Chen, and J-T Fang, and C-W Yang
Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy.
November 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
C-C Jenq, and Y-C Tian, and H-H Wu, and P-Y Hsu, and J-Y Huang, and Y-C Chen, and J-T Fang, and C-W Yang
Intravenous iron and anaemia in haemodialysis patients.
December 1998, Nephron,
C-C Jenq, and Y-C Tian, and H-H Wu, and P-Y Hsu, and J-Y Huang, and Y-C Chen, and J-T Fang, and C-W Yang
[Oral and i.v. iron therapy in haemodialysis patients (author's transl)].
January 1976, L'Ateneo parmense. Acta bio-medica : organo della Societa di medicina e scienze naturali di Parma,
C-C Jenq, and Y-C Tian, and H-H Wu, and P-Y Hsu, and J-Y Huang, and Y-C Chen, and J-T Fang, and C-W Yang
Efficacy and safety of intravenous iron therapy for HCV-positive haemodialysis patients.
January 2005, Nephron. Clinical practice,
C-C Jenq, and Y-C Tian, and H-H Wu, and P-Y Hsu, and J-Y Huang, and Y-C Chen, and J-T Fang, and C-W Yang
[Oral of intravenous iron therapy?].
December 1950, Das Deutsche Gesundheitswesen,
C-C Jenq, and Y-C Tian, and H-H Wu, and P-Y Hsu, and J-Y Huang, and Y-C Chen, and J-T Fang, and C-W Yang
Response of mean reticulocyte haemoglobin content to intravenous iron therapy in haemodialysis patients.
December 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
C-C Jenq, and Y-C Tian, and H-H Wu, and P-Y Hsu, and J-Y Huang, and Y-C Chen, and J-T Fang, and C-W Yang
Iron therapy for haemodialysis patients.
October 1970, Lancet (London, England),
C-C Jenq, and Y-C Tian, and H-H Wu, and P-Y Hsu, and J-Y Huang, and Y-C Chen, and J-T Fang, and C-W Yang
Intravenous administration of iron in epoetin-treated haemodialysis patients.
May 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
C-C Jenq, and Y-C Tian, and H-H Wu, and P-Y Hsu, and J-Y Huang, and Y-C Chen, and J-T Fang, and C-W Yang
[Oral or intravenous iron therapy?].
May 1973, Die Medizinische Welt,
Copied contents to your clipboard!